PH12022551636A1 - Anti-cd73 antibodies and uses thereof - Google Patents

Anti-cd73 antibodies and uses thereof

Info

Publication number
PH12022551636A1
PH12022551636A1 PH1/2022/551636A PH12022551636A PH12022551636A1 PH 12022551636 A1 PH12022551636 A1 PH 12022551636A1 PH 12022551636 A PH12022551636 A PH 12022551636A PH 12022551636 A1 PH12022551636 A1 PH 12022551636A1
Authority
PH
Philippines
Prior art keywords
antibodies
disclosed
vectors
cells
methods
Prior art date
Application number
PH1/2022/551636A
Other languages
English (en)
Inventor
Juan Carlos Almagro
Rebecca A Buonpane
Horacio G Nastri
Shaun M Stewart
Jing Zhou
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PH12022551636A1 publication Critical patent/PH12022551636A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PH1/2022/551636A 2020-01-03 2020-12-30 Anti-cd73 antibodies and uses thereof PH12022551636A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062956847P 2020-01-03 2020-01-03
PCT/US2020/067533 WO2021138467A1 (en) 2020-01-03 2020-12-30 Anti-cd73 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PH12022551636A1 true PH12022551636A1 (en) 2024-01-08

Family

ID=74347717

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/551636A PH12022551636A1 (en) 2020-01-03 2020-12-30 Anti-cd73 antibodies and uses thereof

Country Status (19)

Country Link
US (2) US12018089B2 (https=)
EP (1) EP4084825A1 (https=)
JP (1) JP2023509448A (https=)
KR (1) KR20220121850A (https=)
CN (1) CN115135341A (https=)
AR (1) AR120936A1 (https=)
AU (1) AU2020417804A1 (https=)
BR (1) BR112022013236A2 (https=)
CA (1) CA3166533A1 (https=)
CL (2) CL2022001769A1 (https=)
CO (1) CO2022009248A2 (https=)
CR (1) CR20220317A (https=)
EC (1) ECSP22051701A (https=)
IL (1) IL294436A (https=)
MX (1) MX2022007575A (https=)
PE (1) PE20221409A1 (https=)
PH (1) PH12022551636A1 (https=)
TW (1) TWI873265B (https=)
WO (1) WO2021138467A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CA3166536A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
WO2021138467A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Anti-cd73 antibodies and uses thereof
MX2023007850A (es) * 2020-12-29 2023-09-11 Incyte Corp Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73).
CN113025567A (zh) * 2021-03-31 2021-06-25 中国人民解放军陆军特色医学中心 一种椎间盘单细胞的分离方法
EP4413366A4 (en) * 2021-10-08 2025-09-10 Tiberias Tech Hk Limited TIBTECH METHODS AND COMPOSITIONS FOR THE DETECTION OF CDH17
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025025190A1 (zh) * 2023-08-03 2025-02-06 贝达药业股份有限公司 抗cd73抗体及其应用
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025135233A1 (ko) * 2023-12-21 2025-06-26 ㈜지아이이노베이션 Cd73에 특이적으로 결합하는 항체 및 이의 용도
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
AU5914201A (en) 2000-04-25 2001-11-07 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
EP1360203B1 (en) 2001-01-17 2008-12-24 Intreat Pty Limited Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
EP1639014B1 (en) 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
BRPI0612947A2 (pt) 2005-05-18 2010-12-07 Biogen Idec Inc método para o tratamento de uma condição fibrótica, método para tratar a fibrose pulmonar, método para tratar a fibrose hepática, método para tratar a fibrose renal, métodos para tratar uma doença fibrótica e método para prevenir uma doença fibrótica
EP2975057A1 (en) 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
KR20140126357A (ko) * 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
IL250579B2 (en) 2014-10-10 2023-05-01 Innate Pharma blocking cd73
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
WO2016131950A1 (en) 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
DK3218406T4 (da) 2014-11-10 2024-12-09 Medimmune Ltd Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
EP3218407A1 (en) 2014-11-11 2017-09-20 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
MY189836A (en) * 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
WO2017100670A1 (en) 2015-12-09 2017-06-15 Corvus Pharmaceuticals, Inc. Humanized anti-cd73 antibodies
KR20230038311A (ko) * 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
US11180554B2 (en) 2016-12-13 2021-11-23 Astellas Pharma Inc. Anti-human CD73 antibody
EP3383916B1 (en) * 2017-01-24 2022-02-23 I-Mab Biopharma US Limited Anti-cd73 antibodies and uses thereof
WO2018187512A1 (en) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
CN118307674A (zh) 2017-06-22 2024-07-09 诺华股份有限公司 针对cd73的抗体分子及其用途
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
WO2019170131A1 (zh) 2018-03-07 2019-09-12 复旦大学 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
KR102804816B1 (ko) * 2018-03-09 2025-05-09 페인스 테라퓨틱스 인코포레이티드 항-cd73 항체 및 이의 용도
TWI823906B (zh) * 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
US20210147570A1 (en) 2018-04-12 2021-05-20 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
US20210214459A1 (en) * 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
KR20210100099A (ko) 2018-11-05 2021-08-13 코버스 파마슈티칼스, 인크. B 세포 활성화 cd73 항체
MX2021005396A (es) 2018-11-12 2021-07-06 Jiangsu Hengrui Medicine Co Anticuerpo anti-cd73, fragmento de union a antigeno y aplicacion del mismo.
CN111434688A (zh) 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
CN111499747B (zh) 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
SG11202111106WA (en) 2019-04-23 2021-11-29 Innate Pharma Cd73 blocking antibodies
EA202193351A1 (ru) 2019-06-06 2022-03-21 Джакобио Фармасьютикалс Ко., Лтд. Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы
CN112111008B (zh) 2019-06-19 2024-04-30 海正生物制药有限公司 抗cd73抗体及其应用
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
US20230357425A1 (en) 2019-08-21 2023-11-09 Harbour Biomed (Shanghai) Co., Ltd Anti-cd73 antibody and application thereof
US20210061809A1 (en) 2019-08-26 2021-03-04 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
US11634500B2 (en) 2019-09-06 2023-04-25 Les Laboratoires Servier Anti-CD73 antibodies and compositions
WO2021087463A1 (en) 2019-11-01 2021-05-06 Corvus Pharmaceuticals, Inc. Immunomodulatory anti-cd73 antibodies and uses thereof
EP4058150A2 (en) 2019-11-15 2022-09-21 Genzyme Corporation Biparatopic cd73 antibodies
JP7772700B2 (ja) 2019-12-19 2025-11-18 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 神経膠芽腫を処置するための方法
WO2021138467A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Anti-cd73 antibodies and uses thereof
CA3166536A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
EP4132975A4 (en) 2020-04-09 2024-10-23 Aprilbio Co., Ltd MONOCLONAL ANTIBODIES AND THEIR ANTIGEN-BINDING FRAGMENTS FOR SUPPRESSING THE CD73 IMMUNE CHECKPOINT AND USES THEREOF
BR112022021397A2 (pt) 2020-04-22 2023-02-07 Akeso Biopharma Inc Anticorpo anti-cd73, polipeptídeo isolado, molécula de ácido nucleico, vetor, célula hospedeira, conjugado, proteína de fusão ou anticorpo multiespecífico, kit, composição farmacêutica, uso do anticorpo e linhagem celular de hibridoma
CN115551889A (zh) 2020-05-12 2022-12-30 普米斯生物技术(珠海)有限公司 抗cd73抗体及其用途
EP4159763A4 (en) 2020-05-29 2024-06-12 BrightPath Biotherapeutics Co., Ltd. ANTI-CD73 ANTIBODIES AND USE THEREOF
CN115734972A (zh) 2020-06-22 2023-03-03 信达生物制药(苏州)有限公司 抗cd73抗体及其用途
MX2023007850A (es) 2020-12-29 2023-09-11 Incyte Corp Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73).

Also Published As

Publication number Publication date
JP2023509448A (ja) 2023-03-08
CL2024002235A1 (es) 2024-12-27
TWI873265B (zh) 2025-02-21
BR112022013236A2 (pt) 2022-09-06
CA3166533A1 (en) 2021-07-08
US12018089B2 (en) 2024-06-25
CR20220317A (es) 2022-09-02
AU2020417804A1 (en) 2022-07-21
ECSP22051701A (es) 2022-08-31
TW202128768A (zh) 2021-08-01
WO2021138467A1 (en) 2021-07-08
PE20221409A1 (es) 2022-09-20
AR120936A1 (es) 2022-03-30
CN115135341A (zh) 2022-09-30
EP4084825A1 (en) 2022-11-09
MX2022007575A (es) 2022-09-23
KR20220121850A (ko) 2022-09-01
CL2022001769A1 (es) 2023-01-20
US20240352143A1 (en) 2024-10-24
IL294436A (en) 2022-09-01
US20210230293A1 (en) 2021-07-29
CO2022009248A2 (es) 2022-08-19

Similar Documents

Publication Publication Date Title
PH12022551636A1 (en) Anti-cd73 antibodies and uses thereof
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
EP4339287A3 (en) Modified cells and methods of therapy
PH12020551907A1 (en) Antagonizing cd73 antibody
NZ790656A (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
ZA202205644B (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
MX2021002415A (es) Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas.
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
EP4431607A3 (en) High-throughput precision genome editing
EP4338799A3 (en) Tumor infiltrating lymphocytes and methods of therapy
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
BR112022005114A2 (pt) Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
WO2022082073A3 (en) Compositions and methods for muc18 targeting
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
ZA202401321B (en) Anti-cd161 antibodies and uses thereof
SA523451582B1 (ar) Ccr8 الأجسام المضادة لـ
WO2018169901A8 (en) Synthetic promoters
BR112022012867A2 (pt) Tratamento de câncer com inibidores de cdk12/13
ZA202404295B (en) Anti-mutant calreticulin (calr) antibodies and uses thereof
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof